Project Grant R21CA296516
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$181K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23219, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $816,554 to The University of Texas MD Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) in the context of colorectal cancer. The project aims to assess the impact of tumor growth and surgical resection on the subsequent development of pain hypersensitivity in...
This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University provides $601,091 over a 5-year period starting April 1, 2025 to research damage-associated molecular patterns and their role in paclitaxel-induced peripheral neuropathy. The research aims to characterize the mechanism by which the inflammatory protein S100A9 contributes to this debilitating side effect of the chemotherapy drug paclitaxel, determine an optimal...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) Division. The $179,403 grant, awarded on April 1, 2025, will fund research to develop novel flupirtine analogue compounds that can effectively relieve chemotherapy-induced neuropathic pain (CINP) in cancer patients while addressing the safety concerns associated with the parent flupirtine...
This federal Project Grant award, R01CA273001, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $402,874 award will fund research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN), a significant adverse effect experienced by cancer patients receiving paclitaxel infusion. The research aims to determine if the acute over-excitation...
This $1,239,420 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports a longitudinal observational study on the role of interoception (the brain's processing of bodily sensations) in chemotherapy-induced peripheral neuropathy (CIPN). The study will assess changes in interoception and its relationship to CIPN symptoms in 120 patients with breast or gastrointestinal cancer before, during, and after receiving taxane- or...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate inhibition of the diacylglycerol lipase A (DAGLA) enzyme as a novel strategy to mitigate the nephrotoxicity (kidney damage) caused by the chemotherapy drug cisplatin. The $227,221 award to Virginia Commonwealth University, with a sub-award to the University of Missouri System, will fund research to determine if DAGLA inhibition protects the kidneys against cisplatin-induced...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $5,666,172 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to New York University (NYU) to conduct research on targeting Schwann cell dysfunction and repair signaling in chemotherapy-induced painful peripheral neuropathy (CIPPN). The research aims to study the role of the peroxisome proliferator activated receptor gamma (PPARG) and low-density lipoprotein receptor related protein 1 (LRP1)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $661,122 in funding to The Trustees of Columbia University in the City of New York to investigate the pathogenic role of tubulin post-translational modifications in chemotherapy-induced peripheral neuropathy (CIPN). The research aims to evaluate whether the accumulation of delta-2 tubulin, an irreversible tubulin modification, plays a common pathogenic role in the neuropathic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $391,325.00 to the University of Arizona to develop a new portable confocal microscope that can rapidly image Meissner's corpuscles, which are microscopic nerve endings associated with chemotherapy-induced peripheral neuropathy (CIPN). The goals are to evaluate the clinical utility of this portable confocal microscopy (PCM) technology for assessing CIPN, and to develop deep...